Werewolf Therapeutics (NASDAQ:HOWL) Given “Outperform” Rating at Wedbush

Werewolf Therapeutics (NASDAQ:HOWL)‘s stock had its “outperform” rating reiterated by analysts at Wedbush in a report issued on Wednesday,Benzinga reports. They presently have a $8.00 price target on the stock.

HOWL has been the subject of a number of other reports. JMP Securities cut their target price on Werewolf Therapeutics from $12.00 to $4.00 and set a “market outperform” rating for the company in a research note on Tuesday, January 14th. HC Wainwright restated a “buy” rating and set a $15.00 price objective on shares of Werewolf Therapeutics in a research report on Wednesday.

Werewolf Therapeutics Price Performance

NASDAQ HOWL traded up $0.04 during trading hours on Wednesday, hitting $1.30. 12,973 shares of the company’s stock traded hands, compared to its average volume of 267,094. The company has a market capitalization of $57.71 million, a PE ratio of -0.85 and a beta of 0.37. The company has a debt-to-equity ratio of 0.29, a current ratio of 10.10 and a quick ratio of 10.10. Werewolf Therapeutics has a 52-week low of $1.03 and a 52-week high of $6.89. The firm’s 50-day moving average is $1.37 and its 200-day moving average is $1.83.

Werewolf Therapeutics (NASDAQ:HOWL) last posted its quarterly earnings results on Tuesday, March 11th. The company reported ($0.46) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.43) by ($0.03). Werewolf Therapeutics had a negative net margin of 578.80% and a negative return on equity of 58.83%. Equities analysts forecast that Werewolf Therapeutics will post -1.56 EPS for the current fiscal year.

Institutional Investors Weigh In On Werewolf Therapeutics

A number of institutional investors and hedge funds have recently added to or reduced their stakes in HOWL. Walleye Capital LLC grew its holdings in shares of Werewolf Therapeutics by 10.7% during the 3rd quarter. Walleye Capital LLC now owns 108,968 shares of the company’s stock worth $231,000 after purchasing an additional 10,528 shares during the period. PFM Health Sciences LP lifted its position in Werewolf Therapeutics by 4.9% in the third quarter. PFM Health Sciences LP now owns 3,398,747 shares of the company’s stock valued at $7,205,000 after buying an additional 157,673 shares during the last quarter. State Street Corp boosted its stake in Werewolf Therapeutics by 12.4% during the third quarter. State Street Corp now owns 476,439 shares of the company’s stock worth $1,010,000 after buying an additional 52,528 shares during the period. XTX Topco Ltd acquired a new stake in shares of Werewolf Therapeutics during the third quarter valued at about $45,000. Finally, Barclays PLC raised its stake in shares of Werewolf Therapeutics by 130.1% in the 3rd quarter. Barclays PLC now owns 54,810 shares of the company’s stock valued at $116,000 after acquiring an additional 30,990 shares during the period. Hedge funds and other institutional investors own 64.84% of the company’s stock.

Werewolf Therapeutics Company Profile

Werewolf Therapeutics, Inc, a biopharmaceutical company, develops therapeutics engineered to stimulate the body's immune system for the treatment of cancer. The company, through its proprietary PREDATOR platform, designs conditionally activated molecules that stimulate adaptive and innate immunity for addressing the limitations of conventional proinflammatory immune therapies.